Methylation of S100A8 is a promising diagnosis and prognostic marker in hepatocellular carcinoma
Metrics: PDF 983 views | HTML 1632 views | ?
Kun Liu1,5,*, Yuening Zhang1,*, Chengdong Zhang1,6,*, Qinle Zhang 2,*, Jiatong Li1,*, Feifan Xiao1, Yingfang Li3, Ruoheng Zhang1, Dongwei Dou1, Jiezhen Liang4, Jian Qin7, Zhidi Lin1, Dong Zhao1, Min Jiang1, Zhenxin Liang1, Jie Su8, Vanaparthy Pranay Gupta1, Min He7, Xiaoli Yang1
1Medical Scientific Research Center, Guangxi Medical University, Nanning, Guangxi 530021, China
2Genetic and Metabolic Central Laboratory, The Maternal and Children Health Hospital of Guangxi, Guangxi 530002, China
3Department of Endocrinology, Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi, 545005, China
4Department of Otolaryngology-Head and Neck Surgery, First Affiliated Hospital of Guangxi Medical University, Guangxi 530021, China
5Department of Gastroenterology, The Third Hospital of Nanchang City, Jiangxi 330009, China
6Department of Microbiology and Microbial Engineering, School of Life Sciences, Fudan University, Shanghai 200438, China
7School of Public Health, Guangxi Medical University, Guangxi 530021, China
8Key Laboratory of Early Prevention and Treatment for Regional High Frequency, Ministry of Education, Guangxi Medical University, Nanning, Guangxi 530021, China
*These authors have contributed equally to this work
Xiaoli Yang, email: firstname.lastname@example.org
Min He, email: email@example.com
Keywords: hepatocellular carcinoma, S100A8, DNA methylation, pyrosequencing, prognosis
Received: October 03, 2015 Accepted: June 29, 2016 Published: July 23, 2016
The abnormality of DNA methylation is one of the major epigenetic alterations in the human hepatocellular carcinoma (HCC). We have assessed the global genomic DNA methylation profiles in human HCC patients by using the Infinium Human Methylation27 BeadChip. A CpG loci of S100A8 was found to be significantly hypomethylated in HCC.
Pooled meta-analysis of five validation public datasets demonstrated its methylation level was significantly lower for HCC compared to paired adjacent normal tissues. Quantitative pyrosequencing analysis also showed that the S100A8 methylation level was decreased in cancer tissues (31.90%±13.31%) than that in the paired adjacent normal tissues (65.33%±3.64%, p<0.01). The area under the ROC curve (AUC) value was 0.950 (p<0.01). Kaplan-Meier survival curves revealed that hypomethylation of S100A8 was associated with shortened overall survival (OS) and progression-free survival (PFS) (log rank p<0.05). Multivariate Cox proportional hazards model also indicated significantly shorter OS (HR, 1.709; 95 % CI, 1.127–2.591) and PFS (HR, 1.767; 95 % CI, 1.168–2.974) were observed in the low-methylation-level group compared to the high-methylation-level group. Furthermore, S100A8 overexpression in Huh7 and MHCC-97H hepatoma cell lines led to increased cell proliferation, migration, invasion, and tumor growth. These findings suggested S100A8 methylation to be served as potential diagnosis and prognosis marker for HCC. S100A8 also may play as a tumor promoter in HCC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.